Cargando…

Regulation of PD-L1 expression in the tumor microenvironment

Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Ming, Niu, Mengke, Xu, Linping, Luo, Suxia, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792099/ https://www.ncbi.nlm.nih.gov/pubmed/33413496 http://dx.doi.org/10.1186/s13045-020-01027-5

Ejemplares similares

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
por: Yi, Ming, et al.
Publicado: (2021)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

The role of cancer-derived microRNAs in cancer immune escape
por: Yi, Ming, et al.
Publicado: (2020)

Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cells
por: Niu, Mengke, et al.
Publicado: (2020)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
por: Jiang, Xianjie, et al.
Publicado: (2019)

Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study
por: Yi, Ming, et al.
Publicado: (2021)

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
por: Yi, Ming, et al.
Publicado: (2022)

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
por: Yi, Ming, et al.
Publicado: (2022)

CD44 as a tumor biomarker and therapeutic target
por: Xu, Hanxiao, et al.
Publicado: (2020)

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
por: Yi, Ming, et al.
Publicado: (2021)

CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer
por: Yu, Shengnan, et al.
Publicado: (2020)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
por: Qian, Jiawen, et al.
Publicado: (2018)

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
por: Koirala, Pratistha, et al.
Publicado: (2016)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
por: Wu, Yuze, et al.
Publicado: (2022)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
por: Yuan, Keyu, et al.
Publicado: (2022)

Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity
por: Yan, Yuheng, et al.
Publicado: (2022)

PD-L1: expression regulation
por: Zhou, Yu-Jie, et al.
Publicado: (2023)

Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
por: Shklovskaya, Elena, et al.
Publicado: (2020)

The elevated glutaminolysis of bladder cancer and T cells in a simulated tumor microenvironment contributes to the up-regulation of PD-L1 expression by interferon-γ
por: Wang, Liping, et al.
Publicado: (2018)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction
por: Li, Shiyu, et al.
Publicado: (2020)

The roles of exosomes in cancer drug resistance and its therapeutic application
por: Li, Shiyu, et al.
Publicado: (2020)

MiRNA-mediated EMT and CSCs in cancer chemoresistance
por: Dong, Bing, et al.
Publicado: (2021)

GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors
por: Fu, Yujie, et al.
Publicado: (2020)

Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression
por: Brcic, Iva, et al.
Publicado: (2023)

Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review
por: Wang, Nuo-Han, et al.
Publicado: (2022)

The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
por: Hou, Bo, et al.
Publicado: (2023)

PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
por: Furuse, Motomasa, et al.
Publicado: (2020)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
por: Wu, Kongju, et al.
Publicado: (2019)

PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments
por: Valentini, Anna Maria, et al.
Publicado: (2018)

SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma
por: Yang, Hui, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ial1kcl7ct2o12s8740v0rcn84